Antidiabetic pharmacology: A link between metabolic syndrome and neuro-oncology?

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 409-413

  Aldea, M ^a   Tomuleasa, Ciprian ^a   Petrushev, B ^a   Susman, S ^a   Kacso, G L ^a   Irimie, A ^a   Florian, I S ^b   Soritau, O ^a  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cancer stem cell metabolism; Chemotherapy; Glioma; Metformin

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ALDEHYDE REDUCTASE; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; EVEROLIMUS; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEXOKINASE; HYDROGEN PEROXIDE; METFORMIN; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TEMSIROLIMUS; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER STEM CELL; CELL METABOLISM; DNA DAMAGE; ENZYME ACTIVATION; GLUCOSE TRANSPORT; HUMAN; KIDNEY CARCINOMA; METABOLIC SYNDROME X; NERVOUS SYSTEM TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BRAIN NEOPLASMS; GLUCOSE TRANSPORTER TYPE 3; GLUTATHIONE; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; REACTIVE OXYGEN SPECIES;

EID: 80053966813     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Jordan CT, Guzman ML, Noble N. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261. (Pubitemid 44427449)
2. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 2010; 19: 61-67.
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361(9353): 323-331.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
5. Stupp R, Tonn JC, Brada M, Pantheroudakis G. High-grade malignant gliomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v190-v193.
6. Albesiano E, Han JE, Lin M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 2010; 21: 17-29.
7. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-1308.
8. Jalving M, Gietema JA, Lefrandt JD et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-2380.
9. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 2009; 89: 777-798.
10. Lineham WM, Srinivasam R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7: 277-285.
11. Emerling BM, Weinberg F, Snyder C et al. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic Biol Med 2009; 46: 1386-1391.
12. Grisouard J, Timper K, Radimerski TM et al. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol 2010; 80: 1736-1745.
13. Stockhammer F, von Deimling A, Synowitz M, Blechmidt C, van Landeghem FK. Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. J Mol Histol 2008; 39: 553-560.
14. Brooks GA. Cell-cell and intracellular lactate shuttles. J Physiol 2009; 587: 5591-5600.
15. Jezek P, Plecita-Hlavata L, Smolkova K, Rossignol R. Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development. Int J Biochem Cell Biol 2010; 42: 604-622.
16. Peng TI, Jou MJ. Oxidative stress caused by mitochondrial calcium overload. Ann N Y Acad Sci 2010; 1201: 183-188.
17. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unraveling the mechanism. Lancet 2010; 375(9733): 2267-2277.
18. Corti A, Casini AF, Pompella A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch Biochem Biophys 2010; 500: 107-115.
19. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of poly-o1 pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003; 14(8 Suppl 3): S233-236.
20. Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 2010; 16: 3322-3328.
21. Jones KL. Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-1187.
22. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
23. Amato RJ. Current immunotherapeutic strategies in renal cell carcinoma. Surg Oncol Clin N Am 2007; 16: 975-986. (Pubitemid 350110402)
24. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004; 14: 259-266. (Pubitemid 38903230)
25. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 2010; 1205: 192-198.
26. BARI 2D Study Group, Frye RL, August P et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
27. Martin-Castillo B, Dorca J, Vazquez-Martin A et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an outgoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 2010; 21: 187-189.
28. Chong CR, Chamber BA. Mysterious metformin. Oncologist 2009; 14: 1178-1181.
29. Berstein LM, Yue W, Wang JP, Santen RJ. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat 2010 (in press).
30. Liu B, Fan Z, Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031-2040.
31. Kaida H, Ishibashi M, Yuzuriha M et al. Glucose transporter expression of an esophageal gastrointestinal tumor detected by F-18 FDG PET/CT. Clin Nucl Med 2010; 35: 5050-5059.
32. Ayala FR, Rocha RM, Carvalho KC et al. GLUT1 and GLUT3 as prognostic markers for oral squamous cell carcinoma. Molecules 2010; 15: 2374-2387.
33. Liu Y, Li YM, Tian RF et al. The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res 2009; 1304: 149-154.
34. Boado RJ, Black KL, Partridge WM. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 1994; 27: 51-57. (Pubitemid 24324088)